je.st
news
Tag: pivotal
Chinese Mainland Pivotal in Hong Kong's Food Quality, Safety
2017-07-03 02:00:00| ThePigSite - Industry News
HONG KONG - Food supplied by the Chinese mainland has played a crucial role in improving the livelihoods of residents in Hong Kong since its return to the nation 20 years ago, and the special administrative region is expected to continue enjoying high-quality, safe food products.
Tags: quality
food
safety
hong
Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint
2016-10-19 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
study
primary
medicine
3 pivotal numbers in upcoming Hogs and Pigs Report
2016-09-28 17:56:00| National Hog Farmer
The volatility in the hog market this week illustrates the trade is nervous about the upcoming USDA Hogs and Pigs Report. Market analysts note three significant numbers hog producers should pay attention to in the report. read more
Tags: report
numbers
upcoming
pigs
Pivotal to sell LNG to US company Carib Energy
2016-09-02 01:00:00| Hydrocarbons Technology
Pivotal LNG has signed an agreement to sell liquefied natural gas (LNG) to US-based Carib Energy, a subsidiary of Crowley Maritime.
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
2016-06-11 17:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »